Fedratinib and Nepafenac Ophthalmic
Determining the interaction of Fedratinib and Nepafenac Ophthalmic and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation. MANAGEMENT: Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. References "Product Information. Acular (ketorolac)." Allergan Inc, Irvine, CA. "Product Information. Xibrom (bromfenac ophthalmic)." ISTA Pharmaceuticals, Irvine, CA. "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
Professional:MONITOR: Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.
MANAGEMENT: Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
- "Product Information. Acular (ketorolac)." Allergan Inc, Irvine, CA.
- "Product Information. Xibrom (bromfenac ophthalmic)." ISTA Pharmaceuticals, Irvine, CA.
- "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
Generic Name: nepafenac ophthalmic
Brand name: Nevanac, Ilevro
Synonyms: Nepafenac
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fedratinib-NephPlex RX
- Fedratinib-NephrAmine
- Fedratinib-NephrAmine 5.4%
- Fedratinib-Nephrocaps
- Fedratinib-Nephrocaps-QT
- Fedratinib-Nephron FA
- Nepafenac Ophthalmic-Fedratinib Hydrochloride
- Nepafenac Ophthalmic-Feiba
- Nepafenac Ophthalmic-Feiba NF
- Nepafenac Ophthalmic-Feiba VH Immuno
- Nepafenac Ophthalmic-Feiba-VH
- Nepafenac Ophthalmic-Felbamate